	US 12,226,470 B2
	Pneumococcal dosing regimen
George Rainer Siber, New York, NY (US); Peter R. Paradiso, Radnor, PA (US); Jill Hackell, New City, NY (US); Stephen Paul Lockhart, Hurst (GB); and William P. Hausdorff, Brussels (BE)
Assigned to WYETH LLC, New York, NY (US)
Filed by Wyeth LLC, New York, NY (US)
Filed on Oct. 5, 2021, as Appl. No. 17/494,235.
Application 17/494,235 is a division of application No. 16/520,443, filed on Jul. 24, 2019, granted, now 11,167,020.
Application 14/322,167 is a division of application No. 11/740,580, filed on Apr. 26, 2007, granted, now 8,808,707, issued on Aug. 19, 2014.
Application 16/520,443 is a continuation of application No. 15/598,943, filed on May 18, 2017, granted, now 10,406,220, issued on Sep. 10, 2019.
Application 15/598,943 is a continuation of application No. 14/322,167, filed on Jul. 2, 2014, granted, now 9,669,084, issued on Jun. 6, 2017.
Claims priority of provisional application 60/799,053, filed on May 8, 2006.
Prior Publication US 2022/0023407 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/09 (2006.01); A61K 39/385 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/092 (2013.01) [A61K 39/02 (2013.01); A61K 39/385 (2013.01); A61K 2039/6037 (2013.01)]

11 Claims

1. A method of immunizing against a Streptococcus pneumoniae-caused disease in a subject who is at least 50 years of age and has previously received a 23-valent pneumococcal unconjugated polysaccharide vaccine,

wherein said method comprises administering to said subject an immunogenic amount of a pneumococcal polysaccharide conjugate vaccine comprising polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and

wherein said pneumococcal polysaccharide conjugate vaccine is administered to said subject at least one year after the subject received the 23-valent pneumococcal unconjugated polysaccharide vaccine.